On this page
Idiopathic pulmonary fibrosis
IPF gradually worsens over time, making it harder to breathe. It primarily affects adults, typically over 50 years old, and its exact cause is unknown, though genetic and environmental factors are thought to play a role.
Overview
Idiopathic pulmonary fibrosis (IPF) is a serious, long-term lung condition characterised by the progressive scarring of the lung tissue [PMID:33671241]. This scarring, known as fibrosis, makes the lungs stiff and less able to transfer oxygen into the bloodstream. The term 'idiopathic' means that the cause of the condition is unknown. IPF is a type of interstitial lung disease, affecting the tissue and space around the air sacs of the lungs. The disease typically progresses over time, leading to increasing breathing difficulties.
IPF is a relatively rare condition. Estimates suggest it affects between 3 to 18 people per 100,000 worldwide [PMID:29221118]. It is more commonly diagnosed in individuals over the age of 50 and appears to affect men slightly more often than women. The impact of IPF can vary greatly among individuals; for some, the disease progresses quickly, while for others, it may advance more slowly.
Symptoms & clinical features
The symptoms of idiopathic pulmonary fibrosis often develop gradually over several months or even years. The most common initial symptoms are shortness of breath, particularly during or after physical activity, and a persistent dry cough [PMID:33671241]. As the disease progresses, these symptoms tend to worsen, making even routine daily activities challenging.
Other symptoms that may occur include fatigue, unexplained weight loss, and 'clubbing' of the fingers or toes. Finger clubbing is a physical sign where the fingertips and toenails become wider and rounder than usual. In some cases, individuals with IPF may also experience crackling sounds in their lungs, which a doctor might hear through a stethoscope.
Video: Genetics 101
Affected organs
Idiopathic pulmonary fibrosis primarily affects the lungs. The condition causes progressive scarring and thickening of the interstitial tissue - the delicate network that supports the air sacs (alveoli) in the lungs. This scarring damages the lung structure, reducing its elasticity and ability to function effectively. Over time, the scarred areas prevent oxygen from passing from the lungs into the blood, leading to a shortage of oxygen in the body.
Risks & severity
The severity of idiopathic pulmonary fibrosis can vary significantly between individuals. For some, the condition may progress slowly over many years, while for others, it can worsen more rapidly. The disease is chronic and progressive, meaning it does not resolve and typically becomes more severe over time. Acute exacerbations, which are sudden and severe worsenings of breathing difficulties, can occur and may require urgent medical attention.
Risk factors for developing IPF are not fully understood, but evidence suggests a combination of genetic predisposition and environmental exposures may play a role. Smoking is a well-established risk factor, and certain environmental exposures, such as dust from farming, hairdressing, or stonemasonry, may also increase risk. IPF is more commonly diagnosed in older adults, typically after the age of 50 [PMID:29221118].
Genetic causes
While idiopathic pulmonary fibrosis is considered 'idiopathic' because its primary cause is unknown, research indicates that genetic factors contribute to an individual's susceptibility. Several genes have been identified that are associated with an increased risk of developing IPF, or with the severity of the disease [PMID:29221118].
For example, variants in the *MUC5B* gene are commonly associated with IPF risk. *MUC5B* provides instructions for making a protein that is a major component of mucus in the airways. Other genes implicated include *TERT* and *TERC*, which are involved in maintaining telomeres, protective caps at the ends of chromosomes. Variants in these genes can lead to telomere shortening, which may contribute to the ageing process of lung cells and the development of fibrosis [PMID:33671241]. Additionally, the *TOLLIP* gene is associated with immune responses and inflammation, and variants here have also been linked to IPF risk. these genetic changes do not directly cause IPF in all individuals, but rather increase the likelihood of developing the condition, often in combination with other genetic and environmental factors.
Inheritance pattern
Idiopathic pulmonary fibrosis is generally considered a complex or polygenic condition. This means that its development is influenced by a combination of multiple genetic factors, along with environmental influences. It does not follow a simple Mendelian inheritance pattern, such as autosomal dominant or recessive inheritance.
While IPF itself is not typically inherited in a straightforward manner, a family history of the condition can increase an individual's risk. This is sometimes referred to as 'familial pulmonary fibrosis', which represents a small proportion of all IPF cases. In these families, multiple individuals may develop the disease, suggesting a stronger genetic component, although the specific inheritance pattern can still be complex. For most people with IPF, there is no clear family history of the disease.
Diagnosis & testing
Diagnosing idiopathic pulmonary fibrosis involves a thorough assessment by a healthcare professional, often a respiratory specialist. This process typically includes reviewing a person's medical history, conducting a physical examination, and performing various tests. These tests may include lung function tests, which measure how well the lungs are working, and high-resolution computed tomography (HRCT) scans of the chest [PMID:33671241]. HRCT scans are crucial for identifying the characteristic scarring patterns in the lungs consistent with IPF.
In some cases, a lung biopsy, where a small tissue sample is taken from the lung for microscopic examination, may be necessary to confirm the diagnosis, especially when HRCT findings are not definitive. Genetic testing is not routinely used for diagnosing IPF but may be considered in research settings or in cases of suspected familial pulmonary fibrosis. Within the NHS Genomic Medicine Service, referral to clinical genetics services or genetic counsellors might be considered for families with multiple affected members.
Management & lifestyle
While there is currently no cure for idiopathic pulmonary fibrosis, management focuses on slowing disease progression, managing symptoms, and improving quality of life. Treatment options often include specific anti-fibrotic medications, such as pirfenidone or nintedanib, which can help to slow the rate of lung function decline in some individuals [PMID:29221118]. These medications are typically prescribed and monitored by a respiratory specialist.
Other supportive treatments include oxygen therapy to help with shortness of breath, pulmonary rehabilitation programmes to improve lung function and exercise capacity, and vaccination against respiratory infections. Lifestyle adjustments, such as quitting smoking and maintaining a healthy weight, are also important. In severe cases, lung transplantation may be considered for suitable candidates. Regular monitoring by a multidisciplinary team, including respiratory physicians, nurses, and other specialists, is key to managing IPF.
UK care pathway
In the UK, individuals suspected of having idiopathic pulmonary fibrosis are typically referred to a respiratory specialist for diagnosis and ongoing care. The NHS Genomic Medicine Service (GMS) provides a pathway for genetic testing where appropriate, often following referral from a specialist. While there isn't a specific NHS R-code for diagnostic genetic testing for IPF in routine clinical practice, certain genes associated with familial pulmonary fibrosis may be tested as part of broader interstitial lung disease panels through GMS laboratories. Clinical genetics services and genetic counsellors are available to provide support and information regarding genetic aspects of the condition and its implications for family members.
Frequently asked questions
Is IPF hereditary?
While most cases of IPF occur without a clear family history, genetic factors are known to increase susceptibility. If multiple family members have IPF, it's called familial pulmonary fibrosis, suggesting a stronger genetic influence. However, it does not follow a simple inheritance pattern like some other genetic conditions.
What is the typical age of onset for IPF?
Idiopathic pulmonary fibrosis most commonly affects older adults. It is typically diagnosed in individuals over the age of 50, with the risk increasing with age. It is rare for younger adults or children to develop IPF.
Can smoking cause IPF?
Smoking is a significant risk factor for developing idiopathic pulmonary fibrosis. While it is not the sole cause, studies indicate that individuals who smoke or have a history of smoking are at a higher risk of developing the condition compared to non-smokers. Quitting smoking is often recommended to help manage the disease.
Are there any treatments for IPF?
Currently, there is no cure for idiopathic pulmonary fibrosis, but treatments are available to help manage the condition. Anti-fibrotic medications can slow disease progression, and supportive therapies like oxygen, pulmonary rehabilitation, and management of symptoms can improve quality of life. In some cases, a lung transplant might be considered.
What does 'idiopathic' mean in IPF?
The term 'idiopathic' means that the exact cause of the condition is unknown. In the context of IPF, it indicates that doctors cannot identify a specific reason or underlying disease that has led to the lung scarring. This differentiates it from other forms of pulmonary fibrosis that have known causes, such as exposure to certain toxins or other medical conditions.
References
- Strykowski R, Adegunsoye A. Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis. Immunology and allergy clinics of North America. 2023. PMID: 37055085
- Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. The New England journal of medicine. 2018. PMID: 29742380
- Smith JA. The Therapeutic Landscape in Chronic Cough. Lung. 2024. PMID: 38127133
- Mulet A, Signes-Costa J. Idiopathic Pulmonary Fibrosis and Telomeres. Journal of clinical medicine. 2022. PMID: 36498467
- Fujimoto H, Kobayashi T, Azuma A. Idiopathic Pulmonary Fibrosis: Treatment and Prognosis. Clinical medicine insights. Circulatory, respiratory and pulmonary medicine. 2015. PMID: 27980445
- Werderman DS. Idiopathic Pulmonary Fibrosis. Radiologic technology. 2020. PMID: 32102863
- Abramson MJ, Walters EH. Mapping air pollution and idiopathic pulmonary fibrosis. Respirology (Carlton, Vic.). 2021. PMID: 33398912
- Sharma OP. Idiopathic pulmonary fibrosis. Current opinion in pulmonary medicine. 1996. PMID: 9363166